Current Issues of Pharmacy and Medical Sciences

SYM 2206 (a potent non-competitive AMPA receptor antagonist) elevates the threshold for maximal electroshock-induced seizures ..

Curr Issues Pharm Med Sci., Vol.27, No.2, Pages 80-83

Jarogniew J. Luszczki1,2, Magdalena Leszkowicz1, Maria W. Kondrat-Wrobel1, Magdalena Florek-Luszczki3

1 Department of Pathophysiology, Medical University of Lublin, Ceramiczna 1, 20-150 Lublin, Poland
2 Isobolographic Analysis Laboratory, Institute of Rural Health, Jaczewskiego 2, 20-950 Lublin, Poland
3 Department of Public Health, Institute of Rural Health, Jaczewskiego 2, 20-950 Lublin, Poland

DOI: 10.2478/cipms-2014-0018

 

Abstract

SYM 2206 (a potent non-competitive AMPA receptor antagonist) elevates the threshold for maximal electroshock-induced seizures in mice
 
The aim of this study was to determine the effect of SYM 2206 (a potent non-competitive AMPA receptor antagonist) on the threshold for maximal electroshock (MEST)-induced seizures in mice. Electro-convulsions were produced in mice by means of a current (sine-wave, 50 Hz, maximum 500 V, strength from 4 to 14 mA, 0.2-s stimulus duration, tonic hind limb extension taken as the endpoint) delivered via ear-clip electrodes. SYM 2206 administered systemically (i.p.), 30 min before the MEST test, at doses of 2.5 and 5 mg/kg, did not alter the threshold for maximal electroconvulsions in mice. In contrast, SYM 2206 at doses of 10 and 20 mg/kg significantly elevated the threshold for maximal electro-convulsions in mice (P<0.01 and P<0.001). Linear regression analysis of SYM 2206 doses and their corresponding threshold increases allowed for the determination of threshold increasing doses by 20% and 50% (TID20 and TID50 values) that elevate the threshold in drug-treated animals over the threshold in control animals. The experimentally derived TID20 and TID50 values for SYM 2206 were 4.25 and 10.56 mg/kg, respectively. SYM 2206 dose-dependently increased the threshold for MEST-induced seizures, suggesting the anticonvulsant action of the compound in this seizure model in mice.
 

Keywords

SYM 2206, threshold for maximal electroshock-induced seizures, TID20, TID50, mice

References

  1. Behr J. et al.: Kindling enhances kainite receptor-mediated depression of GABAergic inhibition in rat granule cells. Eur. J. Neurosci., 16, 861, 2002.
  2. Ghersi C. et al.: Pharmacological heterogeneity of release-regulating presynaptic AMPA/kainate receptors in the rat brain: study with receptor antagonists. Neurochem. Int., 42, 283, 2003.
  3. Glantz S.A., Slinker B.K.: editors (2001). Primer of applied regression and analysis of variance, second edition. McGraw-Hill Inc.: New York, NY.
  4. Krauss G.L.: Perampanel: a selective AMPA antagonist for treating seizures. Epilepsy Curr., 13, 269, 2013.
  5. Litchfield J.T., Wilcoxon F.: A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther., 96, 99, 1949.
  6. Löscher W., Fassbender C.P., Nolting B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res., 8, 79, 1991.
  7. Löscher W., Wauquier A.: Use of animal models in developing guiding principles for polypharmacy in epilepsy. Epilepsy Res., Suppl. 11, 61, 1996.
  8. Łuszczki J.J., Antkiewicz-Michaluk L., Czuczwar S.J.: Isobolographicanalysis of interactions between 1-methyl-1,2,3,4-tetrahydroiso-quinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol., 602, 298, 2009.
  9. Łuszczki J.J., Czuczwar S.J.: How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol. Rep., 57, 782, 2005.
  10. Łuszczki J.J., Czuczwar S.J.: Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 529, 2007.
  11. Łuszczki J.J. et al.: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Arch. Pharmacol., 373, 169, 2006.
  12. Łuszczki J.J. et al.: Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur. J. Pharmacol., 595, 13, 2008.
  13. Łuszczki J.J. et al.: Stiripentol in a dose-dependent manner elevates the threshold for maximal electroshock-induced seizures in mice. J. Pre-Clin. Clin. Res., 1, 155, 2007.
  14. Pelletier J.C. et al.: Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem., 39, 343, 1996.
  15. Rogawski M.A.: AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol. Scand. Suppl., 197, 9, 2013.
  16. Rogawski M.A., Donevan S.D.: AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv. Neurol., 79, 947, 1999.
  17. Swinyard E.A., Brown W.C., Goodman L.S.: Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther., 106, 319, 1952.
  18. Welch N.C. et al.: Traditional AMPA receptor antagonists partially block Na v1.6-mediated persistent current. Neuropharmacology, 55, 1165, 2008.

Calendar

April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30